Lineas de Investigación
01. Estudio de los mecanismos implicados en la generación del cáncer de piel con búsqueda específica de nuevos factores pronósticos, así como el abordaje terapeútico de las mismas.
02. Prevención del cáncer cutáneo con investigaciones en el campo de la fotoprotección
03. Análisis de la etiopatogenia de la psoriasis y su tratamiento tanto por mecanismos inmunoterapeúticos y fototerapia.
Miembros del grupo
- Todos
- IR
- Co-IR
- Investigador
- Tecnico Laboratorio
- Otro
Estudios Clínicos
Estudio prospectivo, multicéntrico y a largo plazo para evaluar la seguridad y la eficacia de Nemolizumab (CD14152) en sujetos con dermatitis atópica de moderada a grave.
GALDEMA, S.A
Fase: III
Ensayo Clínico Comercial
Ensayo Clínico fase II para evaluar la seguridad y eficacia de dos modelos de piel autóloga creada mediante ingeniería de tejidos en la cirugía reconstructiva del carcinoma basocelular..
Fundación Pública Andaluza Progreso y Salud
Fase: II
Ensayo Clínico Comercial
Estudio aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de nemolizumab (CD14152) en sujetos con dermatitis atópica de moderada a grave..
GALDERMA RESEARCH & DEVELOPMENT S.N.C.
Fase: III
Ensayo Clínico Comercial
Estudio de extensión abierto y multicéntrico para caracterizar la seguridad y la eficacia a largo plazo de BMS-986165 en pacientes con psoriasis en placas de moderada a grave.
BRISTOL-MYERS SQUIBB COMPANY
Fase: III
Ensayo Clínico Comercial
I1F-MC-RHBA. Estudio multicéntrico, aleatorizado, en doble ciego y controlado con placebo, para comparar la eficacia y la seguridad de LY2439821 frente a etanercept y placebo en pacientes con psoriasis en placas de grado moderado a severo
ELI LILLY AND COMPANY
Fase: III
ENSAYO CLINICO COMERCIAL
WA29330. Estudio multicéntrico, aleatorizado, doble ciego, con doble simulación y comparador activo para evaluar la eficacia y la seguridad de rituximab en comparación con MMF en pacientes con pénfigo vulgar
F. HOFFMANN LA ROCHE LTD
Fase: III
ENSAYO CLINICO COMERCIAL
CAIN457A3401. Ensayo abierto, prospectivo, no aleatorizado, multicéntrico para evaluar el efecto de piel blanqueada en los resultados de calidad de vida relacionada con la salud a las 16 y 52 semanas en pacientes con psoriasis en placas de moderada a grave tratados con
NOVARTIS FARMACEUTICA, S.A.
Fase: IV
ENSAYO CLINICO COMERCIAL
SP14019-18. Evaluación de la solución de uso cutáneo SP14019-F-01 para el tratamiento de la dermatitis atópica. Estudio piloto. Estudio Cyclatop
SPHERIUM BIOMED S.L (ANTES JANUS DEVELOPMENT)
Fase: II
ENSAYO CLINICO COMERCIAL
CAIN457A2323. Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 52 semanas de duración para demostrar la eficacia, seguridad y tolerabilidad de inyecciones subcutáneas de secukinumab con jeringas precargadas de 2 ml (300 mg) en pacientes adul
NOVARTIS FARMACEUTICA, S.A.
Fase: III
ENSAYO CLINICO COMERCIAL
M-41008-41. Estudio clínico abierto para evaluar la eficacia y la seguridad a largo plazo de dimetilfumarato en adultos con psoriasis crónica en placas moderada-grave en la práctica clínica (Estudio DIMESKIN 1)
ALMIRALL S.A.
Fase: IV
ENSAYO CLINICO COMERCIAL
Publicaciones científicas
- Todo
- D1
- Q1
- Q2
- Otro
Beach Lifeguards’ Sun Exposure and Sun Protection in Spain
de Troya Martín M, Blázquez Sánchez N, García Harana C, Alarcón Leiva MC, Aguilera Arjona J, et al. Safety and health at work 2021 Jun;12(2):244-248
Booster Effect of a Natural Extract of Polypodium leucotomos (Fernblock (R)) That Improves the UV Barrier Function and Immune Protection Capability of Sunscreen Formulations
Aguilera J, Vicente-Manzanares M, de Gálvez MV, Herrera-Ceballos E, Rodríguez-Luna A, et al. Frontiers in medicine 2021;8():684665
Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort
Hernández-Fernández CP, Carretero G, Rivera R, Ferrándiz C, Daudén E, et al. Acta dermato-venereologica 2021 Jan 4;101(1):adv00354
Factors related to the evolution of quality of life in patients with cervicofacial non-melanoma skin cancer
García-Montero P, de Gálvez-Aranda MV, Blázquez-Sánchez N, Rivas-Ruíz F, Millán-Cayetano JF, et al. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2021 Sep;29(9):5187-5195
Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study
Julià A, Martínez-Mateu SH, Domènech E, Cañete JD, Ferrándiz C, et al. European journal of clinical nutrition 2021 Sep;75(9):1368-1382
Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain
Daudén E, de Lima GPG, Armesto S, Herrera-Acosta E, Vidal D, et al. Dermatology and therapy 2021 Dec;11(6):2207-2215
Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice
Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, Martínez-García EA, Herrera-Ceballos E Dermatologic therapy 2020 May;33(3):e13313
Effect of Nail Thickness on Visible Radiation Transmittance: Implications for New Photodynamic Therapy Technologies in Onychomycosis
de Gálvez EN, Aguilera J, de Gálvez MV, Fonda-Pascual P, Herrera-Ceballos E, et al. Photochemistry and photobiology 2020 Nov;96(6):1267-1272
Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice
Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, Martínez-García E, Herrera-Ceballos E Dermatologic therapy 2020 Nov;33(6):e14202
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
Daudén E, Carretero G, Rivera R, Ferrándiz C, Llamas-Velasco M, et al. Journal of the American Academy of Dermatology 2020 Jul;83(1):139-150
Quality of Life of Cohabitants of People Living with Acne
Martínez-García E, Arias-Santiago S, Herrera-Acosta E, Affleck A, Herrera-Ceballos E, et al. Acta dermato-venereologica 2020 Oct 14;100(17):adv00290
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group
Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E, et al. Journal of the European Academy of Dermatology and Venereology : JEADV 2020 Dec;34(12):2821-2829
Skin and Arterial Wall Deposits of 18F-NaF and Severity of Disease in Patients with Pseudoxanthoma Elasticum
Gutierrez-Cardo A, Lillo E, Murcia-Casas B, Carrillo-Linares JL, García-Argüello F, et al. Journal of clinical medicine 2020 May 8;9(5):
A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis
Dirschka T, Ekanayake-Bohlig S, Dominicus R, Aschoff R, Herrera-Ceballos E, et al. Journal of the European Academy of Dermatology and Venereology : JEADV 2019 Feb;33(2):288-297
Association between seasonal serum folate levels and ultraviolet radiation
Valencia-Vera E, Aguilera J, Cobos A, Bernabó JL, Pérez-Valero V, et al. Journal of photochemistry and photobiology. B, Biology 2019 Jan;190():66-71
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
Aterido A, Cañete JD, Tornero J, Ferrándiz C, Pinto JA, et al. Annals of the rheumatic diseases 2019 Mar;78(3):
Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study
Montes-Torres A, Aparicio G, Rivera R, Vilarrasa E, Marcellán M, et al. The Journal of dermatological treatment 2019 Aug;30(5):461-465
Secukinumab versus ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice
López Jiménez P, Suárez Pérez J, Herrera Acosta E, Aguilera Arjona J, Mendiola Fernández MV, et al. Dermatologic therapy 2019 Jul;32(4):e12937
UVA and UVB Photoprotective Capabilities of Topical Formulations Containing Mycosporine-like Amino Acids (MAAs) through Different Biological Effective Protection Factors (BEPFs)
de la Coba F, Aguilera J, Korbee N, de Gálvez MV, Herrera-Ceballos E, et al. Marine drugs 2019 Jan 14;17(1):
Water-Filtered Infrared Radiation Decreases the Generation of Photodermatoses Dependent on Ultraviolet and Visible Radiation
de Gálvez MV, Aguilera J, Sánchez-Roldán C, Herrera-Acosta E, Herrera-Ceballos E Photochemistry and photobiology 2019 May;95(3):874-878
Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the UK and Republic of Ireland
Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, et al. The British journal of dermatology 2018 Oct;179(4):863-871
Prevalence and predictors of sunburn among beachgoers
de Troya-Martín M, de Gálvez-Aranda MV, Rivas-Ruiz F, Blázquez-Sánchez N, Fernández-Morano MT, et al. Photodermatology, photoimmunology & photomedicine 2018 Mar;34(2):122-129
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm
Belinchón I, Ramos JM, Carretero G, Ferrándiz C, Rivera R, et al. Journal of the European Academy of Dermatology and Venereology : JEADV 2017 Oct;31(10):1700-1708
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry
Pérez-Plaza A, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, et al. Journal of the European Academy of Dermatology and Venereology : JEADV 2017 Jun;31(6):1021-1028
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
Dávila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa JM, et al. The Journal of investigative dermatology 2017 Feb;137(2):313-321
Is mitotic rate still useful in the management of patients with thin melanoma?
Tejera-Vaquerizo A, Pérez-Cabello G, Marínez-Leborans L, Gallego E, Oliver-Martínez V, et al. Journal of the European Academy of Dermatology and Venereology : JEADV 2017 Dec;31(12):2025-2029
Rational Design and Synthesis of Efficient Sunscreens To Boost the Solar Protection Factor
Losantos R, Funes-Ardoiz I, Aguilera J, Herrera-Ceballos E, García-Iriepa C, et al. Angewandte Chemie (International ed. in English) 2017 Mar 1;56(10):2632-2635
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort
García-Doval I, Pérez-Zafrilla B, Ferrandiz C, Carretero G, Daudén E, et al. The Journal of dermatological treatment 2016;27(3):203-9
Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis
Aterido A, Julià A, Ferrándiz C, Puig L, Fonseca E, et al. The Journal of investigative dermatology 2016 Mar;136(3):593-602
Infrared radiation increases skin damage induced by other wavelengths in solar urticaria
de Gálvez MV, Aguilera J, Sánchez-Roldán C, Herrera-Ceballos E Photodermatology, photoimmunology & photomedicine 2016 Sep;32(5-6):284-290
Sun Protection Habits and Attitudes Among Healthcare Personnel in a Mediterranean Population
de Troya-Martín M, Padilla-España L, Férnandez-Morano T, Delgado-Sánchez N, Blázquez Sánchez N, et al. Journal of cancer education : the official journal of the American Association for Cancer Education 2016 Dec;31(4):789-795
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
Dávila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, et al. Journal of the European Academy of Dermatology and Venereology : JEADV 2016 Nov;30(11):1942-1950
A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk
Julià A, Pinto JA, Gratacós J, Queiró R, Ferrándiz C, et al. Annals of the rheumatic diseases 2015 Oct;74(10):1875-81
Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis
Julià A, Ferrándiz C, Dauden E, Fonseca E, Fernández-López E, et al. The pharmacogenomics journal 2015 Aug;15(4):322-5
Defining the dermoscopic characteristics of fast-growing cutaneous melanomas
Tejera-Vaquerizo A, Arias-Santiago S, Nagore E, Martín-Cuevas P, Orgaz-Molina J, et al. Melanoma research 2015 Jun;25(3):269-72
Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma
Tejera-Vaquerizo A, Nagore E, Puig S, Robert C, Saiag P, et al. European journal of cancer (Oxford, England : 1990) 2015 Sep;51(13):1780-93
Human Hair as a Natural Sun Protection Agent: A Quantitative Study
de Gálvez MV, Aguilera J, Bernabó JL, Sánchez-Roldán C, Herrera-Ceballos E Photochemistry and photobiology 2015 Jul-Aug;91(4):966-70
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry
Carretero G, Ferrandiz C, Dauden E, Vanaclocha Sebastián F, Gómez-García FJ, et al. Journal of the European Academy of Dermatology and Venereology : JEADV 2015 Jan;29(1):156-63
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry
Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, et al. Journal of the European Academy of Dermatology and Venereology : JEADV 2015 May;29(5):858-64
Enlaces
Calle Severo Ochoa, 35
Parque Tecnol?gico de Andaluc?a (PTA) Campanillas,
M?laga 29590
(+34) 951 440 260
Fax: (+34) 951 440 263
